BioSpace News Archive

The University of Oklahoma has received funding from the National Institutes of Health to establish the Oklahoma Center of Medical Imaging for Translational Cancer Research.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent #11,278,338 for the Newton™ Knee.

Males presented with more severe carpal tunnel syndrome and were offered surgery more often than females with the condition, according to work by researchers at Hospital for Special Surgery featured in a poster presentation at the American Academy of Orthopaedic Surgeons 2022 Annual Meeting.

Sepha, the Northern Ireland-based manufacturer of pharmaceutical packaging and equipment, has developed a new compact small-batch blister packaging machine with full traceability and electronic data storage capabilities.

Alchemab Therapeutics, has been selected by NVIDIA to harness the power of the UK’s most powerful supercomputer, Cambridge-1. Alchemab will use the NVIDIA DGX SuperPOD supercomputing cluster.

Cementless knee replacement, an alternative approach to traditional cemented knee replacement surgery, is garnering interest in the field of orthopedic surgery.

OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its Board of Directors has appointed Nancy Gagliano, MD to serve as interim Chief Executive Officer, effective April 1, 2022.

Talaris Therapeutics, Inc. announced that members of its senior management team will participate at the following investor conferences:

MediWound Ltd., a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, announced that the underwriter of its recently completed public offering of ordinary shares, which closed on March 7, 2022, partially exercised their over-allotment option, having purchased an additional 623,082 ordinary shares.

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, provides a business update and reports financial results for the three and twelve months ended December 31, 2021.